PLAT and myeloid sarcoma: Interestingly, and consistently, plasma plasminogen activator inhibitor-1 (PAI-1) levels were found to be significantly higher in MS case controls, specifically RRMS cases, consistently with our finding of a higher plasma PLAT decrease found in RRMS cases compared to healthy controls (as described previously) [61].